IGHE
Alpha Lifetech can provide IGHE corresponding products, help each customer's research and development.
01
Introduction To IGHE
Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to IGHE is a common target in medicine.
IGHE, also known as the immunoglobulin heavy chain constant region ε (immunoglobulin heavy constant epsilon). IGHE is a gene encoding the constant region of the human immunoglobulin E (IgE) heavy chain and is essential for the production and function of IgE. The IgE protein encoded by IGHE, as a kind of immunoglobulin, its basic structure consists of four peptide chains, including two heavy chains (Heavy chain, H chain) and two light chains (Light chain, L chain) IgE is an important immunoglobulin involved in allergic reaction and immune regulation.
Function of Target IGHE
The IGHE, but as a part of the heavy chain constant region (C region), has a significant impact on the various biological functions of Ig. Ig (including Ig types containing IGHE) specifically binds antigens such as toxins and viruses, preventing them from binding to receptors on the cell surface and thus neutralizing their virulence or infectivity. By specifically binding to antigens, Ig mediates the immune effects of humoral immunity to protect the body from pathogens. Ig can activate the complement system, a cascade that ultimately leads to the labeling, phagocytosis, and clearance of pathogens. Ig types containing IGHE play the same role in this process. Mediates phagocytic opsonization: binding to Fc receptors on the surface of phagocytes (e.g., macrophages) to enhance the ability of phagocytes to recognize and phagocytose antigen. The killing of immune cells (such as NK cells) on target cells.
Gene Pathway of Target IGHE
IgE binds to the high-affinity Fc ε RI (FCER1A) receptor on the cell surface of mast cells, basophils, etc., through its Fc segment. When IgE binds to a specific antigen (e.g., allergen), Fc ε RI undergoes conformational changes leading to receptor aggregation and activation of downstream signaling pathways.
Activation of Fc ε RI triggers a series of intracellular signal transduction events, including phosphorylation, activation of protein kinases, etc. These signal transduction events eventually lead to cell degranulation, and the release of inflammatory mediators (such as histamine, leukotrienes, etc.), triggering allergic reactions. The released inflammatory mediators act on the surrounding tissues, causing vascular expansion, increased permeability, smooth muscle contraction, and other reactions, leading to the emergence of allergic symptoms. IgE is also involved in the activation and differentiation of other immune cells, regulating the intensity and direction of immune responses.
Fig 1: IG-E Gene Pathway. (Reference source: Ando T, Kitaura J. Tuning IgE: IgE-Associating Molecules and Their Effects on IgE-Dependent Mast Cell Reactions. Cells. 2021 Jul 5;10(7):1697. )
Alpha Lifetech Can Provide
Currently, various immune drugs targeting IGHE targets are in the updating iteration, and taking the disease alone or in combination with other products has become a new approach with remarkable achievements. The IGHE targets have shown important research value and application prospects in both biology and drug research and development. With further research and detection technology advances, IGHE target products are also essential in medical research. Alpha Lifetech can provide IGHE with corresponding products and help each customer's research and development. Alpha Lifetech provides end-to-end biotechnology development solutions, from upstream cell culture optimization to downstream purification scale. Our process is validated through analytical techniques such as HPLC, SDS-PAGE, and mass spectrometry to ensure product consistency and regulatory compliance. By combining cutting-edge biotechnology expertise with flexible service models, we help clients accelerate project research progress and ensure smooth experimentation.
| Catalog Number | Product Name | Product Sizes |
|---|---|---|
| ADT1412 | 1mg,5mg | |
| ADT1019 | ADT1019-Al-901 Biosimilar-Anti IGHE mAb- Research Grade | 1mg,5mg |
| ADT1360 | ADT1360-Ligelizumab Biosimilar-Anti IGHE mAb- Research Grade | 100ug,1mg,5mg |
| ADT1462 | ADT1462-Omalizumab Biosimilar-Anti IGHE mAb- Research Grade | 100ug,1mg,5mg |
| ADT1527 | ADT1527-Quilizumab Biosimilar-Anti IGHE mAb- Research Grade | 100ug,1mg,5mg |
| ADT1626 | ADT1626-Tanezumab Biosimilar-Anti IGHE mAb- Research Grade | 1mg,5mg |
Reference
[1] Fujii H, Kondo N, Agata H, Fukutomi O, Shinoda S, Kuwabara N, Tomatsu S, Kondo T, Inoue R, Orii T. Genetic analysis of IgE and the IGHE, IGHEP1 and IGHEP2 genes in atopic families. Int Arch Allergy Immunol. 1995 Jan;106(1):62-8.
[2] Tanabe H, Ishida T, Ueda S, Sofuni T, Mizusawa H. Comparative mapping of the immunoglobulin C epsilon 1 gene (IGHE) in five species of nonhuman primates by fluorescence in situ hybridization. Cytogenet Cell Genet. 1995;70(3-4):239-42.
[3] Wagner B. IgE in horses: occurrence in health and disease. Vet Immunol Immunopathol. 2009 Nov 15;132(1):21-30.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
2018-07-16
0102